Alpine Immune Sciences Stock Forecast, Price & News

-0.43 (-4.86 %)
(As of 08/2/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume47,457 shs
Average Volume126,733 shs
Market Capitalization$201.13 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

Alpine Immune Sciences logo

About Alpine Immune Sciences

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.37 out of 5 stars

Medical Sector

181st out of 2,226 stocks

Pharmaceutical Preparations Industry

89th out of 870 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

Is Alpine Immune Sciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alpine Immune Sciences stock.
View analyst ratings for Alpine Immune Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Alpine Immune Sciences?

Wall Street analysts have given Alpine Immune Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alpine Immune Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 850,700 shares, an increase of 47.0% from the June 15th total of 578,700 shares. Based on an average daily trading volume, of 135,000 shares, the days-to-cover ratio is currently 6.3 days. Approximately 6.6% of the shares of the company are short sold.
View Alpine Immune Sciences' Short Interest

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Alpine Immune Sciences

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings data on Wednesday, May, 12th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The biotechnology company earned $3.20 million during the quarter, compared to analysts' expectations of $5.84 million. Alpine Immune Sciences had a negative net margin of 288.70% and a negative trailing twelve-month return on equity of 66.38%.
View Alpine Immune Sciences' earnings history

How has Alpine Immune Sciences' stock been impacted by COVID-19?

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALPN stock has increased by 189.0% and is now trading at $8.41.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ALPN?

4 Wall Street analysts have issued 1 year target prices for Alpine Immune Sciences' shares. Their forecasts range from $18.00 to $21.00. On average, they anticipate Alpine Immune Sciences' stock price to reach $19.33 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price.
View analysts' price targets for Alpine Immune Sciences
or view top-rated stocks among Wall Street analysts.

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the following people:
  • Dr. Mitchell H. Gold M.D., Exec. Chairman & CEO (Age 53, Pay $817.5k)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 50, Pay $758.64k)
  • Mr. Paul Rickey, Sr. VP, CFO, Treasurer & Sec. (Age 42, Pay $551.8k)
  • Dr. Wayne R. Gombotz, Chief Technology Officer (Age 62)
  • Dr. Jan L. Hillson M.D., Sr. VP of Clinical Devel. (Age 68)
  • Dr. Remy Durand Ph.D., Chief Bus. Officer
  • Dr. Pamela Holland Ph.D., Sr. VP of Research
  • Dr. Zelanna Goldberg M.D., Chief Medical Officer

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include New York State Common Retirement Fund (0.04%). Company insiders that own Alpine Immune Sciences stock include Mitchell Gold, Orbimed Advisors Llc and Robert E Conway.
View institutional ownership trends for Alpine Immune Sciences

Which major investors are buying Alpine Immune Sciences stock?

ALPN stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund.
View insider buying and selling activity for Alpine Immune Sciences
or or view top insider-buying stocks.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $8.41.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences has a market capitalization of $201.13 million and generates $9.34 million in revenue each year. The biotechnology company earns $-27,940,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does Alpine Immune Sciences have?

Alpine Immune Sciences employs 57 workers across the globe.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is

Where are Alpine Immune Sciences' headquarters?

Alpine Immune Sciences is headquartered at 188 East Blaine Street Suite 200, Seattle WA, 98102.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.